Objective Hepatitis D virus (HDV) is a circular RNA virus coinfecting hepatocytes with hepatitis B virus. Chronic hepatitis D results in severe liver disease and an increased risk of liver cancer. Efficient therapeutic approaches against HDV are absent.
Design Here, we combined an RNAi loss-of-function and small molecule screen to uncover host-dependency factors for HDV infection.
Results Functional screening unravelled the hypoxia-inducible factor (HIF)-signalling and insulin-resistance pathways, RNA polymerase II, glycosaminoglycan biosynthesis and the pyrimidine metabolism as virus-hepatocyte dependency networks. Validation studies in primary human hepatocytes identified the carbamoyl-phosphatesynthetase 2, aspartate transcarbamylase and dihydroorotase (CAD) enzyme and estrogen receptor alpha (encoded by ESR1) as key host factors for HDV life cycle. Mechanistic studies revealed that the two host factors are required for viral replication. Inhibition studies using N-(phosphonoacetyl)-L-aspartic acid and fulvestrant, specific CAD and ESR1 inhibitors, respectively, uncovered their impact as antiviral targets.
Conclusion The discovery of HDV host-dependency factors elucidates the pathogenesis of viral disease biology and opens therapeutic strategies for HDV cure.
- antiviral therapy
- hepatitis D
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Significance of this study
What is already known on this subject?
Chronic hepatitis D is the most severe form of viral hepatitis.
Efficient therapeutic strategies are absent.
Hepatitis D virus is a small hepatitis B virus satellite virus.
Knowledge about HDV–hepatocyte interactions is limited.
HDV host-dependency factors are largely unknown.
What are the new findings?
A RNAi screen identified oestrogen receptor 1 (ESR1) and CAD as novel host factors for HDV infection.
The inhibition of CAD restricts HDV infection through uridine depletion.
ESR1 and CAD are functionally linked by transcriptional activation of gene expression.
ESR1 and CAD inhibitors fulvestrant and PALA, respectively, specifically inhibit HDV replication in a dose-dependent manner in human hepatocytes.
CAD and ESR1 are previously undiscovered targets for antiviral therapies.
How might it impact on clinical practice in the foreseeable future?
The discovery of HDV host-dependency factors opens the door for novel therapeutic strategies against chronic hepatitis D - a major unmet medical need.
Fulvestrant and PALA-like molecules are candidate compounds for HDV antivirals to enter preclinical development.
Hepatitis delta virus (HDV) infects human hepatocytes and causes acute acerbation of liver disease in patients chronically infected with hepatitis B virus (HBV).1 Among HBV-infected patients, 5%–10% are coinfected with HDV.2 HDV coinfection or surinfection in HBV carriers induces more severe disease compared with infection with HBV alone. This includes a greater likelihood of experiencing liver failure and a more rapid progression to liver cirrhosis, with a markedly increased risk of developing hepatocellular carcinoma.3 Consequently, chronic hepatitis D is considered as one of the most severe forms of viral hepatitis. Treatment with HBV nucleos(t)ide analogues is not effective at reducing HDV replication or disease. Moreover, the virus is only poorly controlled by the current interferon (IFN)-based therapies.3 To date, no treatment allows efficient cure of hepatitis D with eradication of the virus and its associated disease.4–6 Thus, there is a major unmet medical need for curative therapies.
HDV is a small, circular RNA HBV satellite virus related to plant viroids using HBV envelope proteins to assemble its infectious particles.1 5 6 Consequently, it can only be propagated by HBV-infected hepatocytes producing HBV envelope proteins (Hepatitis B surface antigen or HBsAg). The HDV genome is a circular 1.7 kb single-stranded negative-sense RNA molecule (for a review on HDV virology and pathogenesis, see ref 5). The HDV life cycle starts with virus entry into hepatocyte after attachment to heparan sulfate proteoglycans (HSPG) at the cell surface.5 7 As HBV and HDV share the same envelope proteins, they appear to share the same entry pathway and receptor(s), including the sodium taurocholate cotransporting polypeptide (NTCP) and glypican 5 (reviewed in refs 5 6 8). The HDV genome is then imported in the nucleus, and three types of RNAs are transcribed by the host RNA polymerase II: replication is initiated by synthesis of an antigenomic RNA that serves as a template for the production of new HDV genomic RNA and HDV mRNA from genomic RNA.5 mRNA transcripts contain one unique open reading frame encoding the hepatitis delta antigen (HDAg) that exists in two forms (small version [S-HDAg] and large version [L-HDAg]) which play differential roles in the HDV life cycle.5 6 Indeed, S-HDAg is essential to HDV replication, while prenylation of L-HDAg leads to the inhibition of HDV replication and is crucial for binding to HBV envelope proteins and virion assembly.6 In the nucleus, L-HDAgs bind to the de novo HDV genomic RNA to form a new ribonucleoprotein, which is exported to the cytoplasm and interacts with HBsAgs at the endoplasmic reticulum to form new infectious virions that are then secreted to propagate further rounds of HDV infection.6 While the molecular virology of HDV has been elucidated, the role of host-dependency factors for HDV infection remains largely unknown.5
A unique feature of HDV is the apparent lack of non-structural protein encoded by the viral genome (including viral polymerase), making it highly dependent of the host machinery for its replication. Targeting host factors is an emerging concept in the treatment of infectious diseases including hepatitis viruses.9–12 Two host compounds targeting HDV factors have been developed up to clinical proof of concept: these include Myrcludex B, a small peptide targeting HBV/HDV entry factor NTCP, and the prenylation inhibitor lonafranib.4 13 14 Both compounds demonstrated a significant clinical antiviral effect in chronically infected patients,4 13 14 supporting the validity of the concept of host-targeting antivirals for HDV infection. However, data on long-term safety, potential resistance in subsets of patients and sustained virological response remain to be determined. Thus, complementary approaches targeting other host factors and/or steps of the HDV life cycle are needed for curative therapies.
Taking advantage of our recently developed robust HDV infection system for the study of HDV–host factor interactions7 combined with a dual screening approach, we aimed to uncover HDV host-dependency factors as antiviral targets.
A high-throughput RNAi loss-of-function screen uncovers hepatocyte host-dependency factors required for HDV infection
To identify host factors required for HDV infection, we performed a high-throughput loss-of-function screen using the HDV-susceptible cell line Huh-106.7 Since one key goal was the discovery of druggable host targets, we used a library comprising siRNAs targeting 7567 genes, which have been selected as targets for therapeutics, including kinases, proteases, phosphatases, G protein-coupled receptor, ion channels, ubiquitin ligases, proteins involved in senescence, autophagy, DNA repair and targetable nuclear receptors. Huh-106 cells were transfected with siRNAs pools 48 hours before inoculation with HDV (figure 1A) with an optical immunostaining-based viral protein (HDAg) readout 7 days after infection. The silencing of expression of HDV host factor NTCP was used as functional positive control (figure 1B-C). The results of the primary screen are presented in online supplementary table S1 .
Supplementary file 2
Using the hit selection algorithm described in online supplementary material and methods and figure 1E, we identified 191 host factor genes showing a robust correlation between gene silencing and level of HDV infection, moderate toxicity of gene-specific siRNA and their expression in the liver (figure 1D,E and online supplementary table S2). The threshold of hit selection (described in figure 1E) was based on the functional effect of SLC10A1 silencing (approximately 45% decrease in HDV infection, online supplementary table S1). The hit rate of 191 genes corresponds to 2.5% of total genes, which is similar to screens for other virus host factor-dependency screens.15 16
Supplementary file 3
Functional pathway analysis using KEGG pathways identified a network of host factors belonging to HSPG biosynthesis, including EXT1 and EXT2 (figure 2A,B). These genes encode two major exostosins, key HSPG-related enzymes exhibiting glycosyltransferase activities and involved in the elongation of heparan sulfate chains.17 Moreover, several subunits of the RNA polymerase II were identified in our screen (figure 2B), including specific subunits such as POLR2G or POLR2I, encoding Rpb7 and Rpb9, which play key roles in the initiation of transcription and binding to DNA template for an accurate selection of the transcription start sites, respectively.18 19 The identification of HSPG enzymes and RNA polymerase II as known HDV-related pathways5 7 validates our approach for host factor discovery (figure 2). Importantly, the screen identified several previously unknown HDV-related networks, such as the hypoxia inducible factor 1 alpha (HIF-1α) signalling pathway, known to enhance the replication of several RNA and DNA viruses such as Epstein-Barr virus and HIV.20 21 Interestingly, the HIF-1α signalling pathway also plays a key role in hepatocarcinogenesis and liver tumour progression22 23 through its ability to target the expression of oncogenic genes such as the proliferation-specific transcription factor Forkhead box M1.24 HIF-1α overexpression in HCC has been correlated with worse clinical outcomes and is considered as a poor prognosis factor and molecular target for liver disease therapy.24 Interestingly, the highly significant scoring of insulin resistance-related pathways highlights the importance of hepatocyte metabolism as host-dependency factors on HDV infection (figure 2).
Finally, we identified several host factors involved in the biosynthesis of pyrimidine, including CANT1, ENTPD5 and CAD.
The pyrimidine biosynthesis enzyme CAD is a key host factor for HDV infection and antiviral target in human hepatocytes
Given its high impact on HDV infection, functional relevance, liver expression and targetability, we focused on CAD, encoding the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase and dihydroorotase (CAD), an enzyme playing a key role in the pyrimidine biosynthesis (online supplementary table S2; figure 2).25 Silencing of CAD led to a robust decrease in HDV infection (figure 3A). CAD is a trifunctional enzyme catalysing the first steps of pyrimidine biosynthesis.26 Interestingly, CAD expression is known to be regulated by activated estrogen receptor alpha (or estrogen receptor 1, ESR1), which binds to the transcription factor SP1,27 two other host-dependency factors uncovered by the RNAi screen (figure 3A). These data suggest a key role of the pyrimidine biosynthesis pathway and its associated nuclear proteins for the HDV life cycle.
We next investigated the functional role of CAD in HDV infection. We first performed additional silencing studies using individual CAD-specific siRNA. As shown in figure 3B–D, a strong reduction of HDV RNA was observed after transfection of Huh-106 cells with the four individual siRNAs composing the siRNA pool, validating the key role of CAD expression in HDV infection. Notably, CAD expression was not significantly affected by HDV infection (figure 3E).
Aiming to characterise the potential of CAD as an antiviral target, we synthetised a specific inhibitor of CAD, sparfosic acid or N-(phosphonoacetyl)-L-aspartic acid (PALA).26 PALA is an aspartic acid derivative, which inhibits the aspartate carbamoyltransferase activity of the enzyme. We then investigated the antiviral activity of PALA in HDV-infected Huh-106 cells. As shown in figure 3F, PALA dose dependently inhibits HDV infection with an IC50=1.2 µM. Notably, a decrease in cell viability was observed after 7 days of culture.
To validate this result in the most physiological model for HDV infection, we investigated the antiviral activity of PALA using HDV infection of primary human hepatocytes (PHHs). Interestingly, while no toxicity was observed in PHH even at high doses (100 µM), the IC50 of PALA was slightly higher in PHH (figure 3G), which may reflect differences in uridine pools and/or CAD expression in rapidly dividing Huh7-based cells versus non-dividing PHH in cell culture.28
To investigate the mechanism of action of CAD–HDV interaction, we performed a rescue experiment using PALA and uridine-supplemented medium. Northern blot detection of HDV genomic RNA in infected cells revealed that the addition of uridine in PALA-treated cells restored HDV infection, validating the functional relevance of pyrimidine pathway for HDV replication (figure 4A). Notably, PALA at a concentration of 2.5 µM induced a strong decrease in HDV infection, which was efficiently rescued by uridine treatment (figure 4B,C). This dose was then selected for further functional studies. Importantly, no direct interaction was observed between CAD and the HDV antigens (figure 4D). As the inhibition of pyrimidine pathway has been shown to stimulate the innate antiviral response with subsequent inhibition of viral propagation,29 we next assessed the expression of IFNB1 following PALA treatment in Huh-106 cells. As shown in figure 4E, no IFNB1 induction was observed after treatment with either PALA or Brequinar, targeting dihydroorotate dehydrogenase (DHODH), suggesting an absence of innate immune stimulation by pyrimidine inhibitors in hepatocyte-derived cells.
To further validate the involvement of the biological function of CAD in HDV infection, cell culture medium was then complemented using either glutamine (Glu; the initial substrate of CAD) or dihydroorotate (DHO; the final product of CAD) (figure 5A, as described in ref 25). As shown in figure 5B and online supplementary figure S1, while Glu treatment had no effect on intracellular HDV RNA, DHO treatment in PALA-treated cells restored HDV RNA to non-treated levels, suggesting that PALA antiviral activity is linked to CAD physiological function.
Supplementary file 1
To map the replication steps mediated by CAD and targeted by PALA, we performed northern blot analyses of HDV RNA allowing to quantify the HDV genome and antigenome in the presence or absence of PALA. As shown in figure 5C, PALA treatment effectively decreased the levels of both HDV genomic and antigenomic RNAs. Moreover, this inhibition was already observed during the early stages of viral replication (online supplementary figure S1). These data demonstrate that PALA inhibits all the steps of HDV replication including the synthesis of antigenomic RNA (figure 5C).
Next, we performed kinetic studies adding PALA preinfection, peri-infection and HDV postinfection (figure 5D). PALA potently inhibited HDV infection given at any time before, during and following initiation of replication. Interestingly, the inhibitory effect was most pronounced when PALA was added prior or during initiation of replication. Finally, to exclude effects on other steps of the early HDV life cycle, we studied the effect of PALA treatment on HDV binding to the Huh-106 cell surface. The absent effect on HDV binding further confirms HDV replication as the life cycle step targeted by PALA (figure 5E).
To test the specificity of the pyrimidine pathway for HDV infection, we treated HBV-producing HepAD38 cells with PALA. As shown in figure 5F, PALA did not modulate HBV antigen production as shown by an absent effect on HBeAg and HBsAg secretion. While tenofovir (TFV) treatment dose-dependently inhibited HBV replication, PALA had no effect on HBV DNA in the supernatant of HepAD38 cells (figure 5G). Finally, the silencing of CAD expression did not affect HBV infection in HepG2-NTCP cells (figure 5H). These results suggest that the pyrimidine/CAD pathway is relevant for HDV but not HBV replication. Collectively, our results identify CAD as a key HDV host factor involved in HDV replication and target for antiviral therapy.
A small molecule screen uncovers ESR1 inhibitor fulvestrant as host targeting agent
Next, we performed a small molecule screen using the Prestwick library, containing 1280 drugs approved by the Food and Drug Administration (FDA) (figure 6A). Among the molecules exhibiting an antiviral activity against HDV, we identified fluvastatin and cyclosporin A, two well-described NTCP inhibitors (online supplementary table S3), confirming the validity of the screen. Interestingly, ribavirin, a broad antiviral nucleoside analogue30 previously used for the treatment of chronic hepatitis C31 exhibits a marked antiviral activity against HDV (online supplementary table S3). In the same vein, nelfinavir, a protease inhibitor presenting antiretroviral activity32 was also identified in the drug screen (online supplementary table S3).
Supplementary file 4
Given our discovery of ESR1 as HDV host-dependency factor, we next focused on ESR1-targeting agents. The library includes several agonists and antagonists of ESR1, as well as characterised targets for endocrine therapy in breast cancer.33 Interestingly, the ESR1 antagonist fulvestrant exhibited a marked, significant and dose-dependent antiviral effect against HDV, whereas tamoxifen and toremifen, two ESR1 modulators with oestrogenic effects in the liver34 increased HDV infection, validating the importance of ESR1 in HDV infection (figure 6B-C). Interestingly, a 48-hour treatment started after virus inoculation induced a marked decrease in HDV-infected cells (figure 5D), suggesting an effect on HDV replication.
Next, we aimed investigate the mechanism of action of the antiviral activity of fulvestrant by investigating a functional link of ESR1 and CAD suggested by protein/protein interaction studies.27 To address this question, CAD expression was analysed in Huh-106 cells and PHH in the presence or absence of the ESR1 antagonist (figure 6E-G). As shown in figure 6G, fulvestrant treatment resulted in a loss of CAD protein expression in both Huh-106 cell line and PHH, suggesting that the antiviral activity of ESR1-inhibitor fulvestrant is mediated by ESR1-mediated downregulation of CAD expression, which in turn is required for HDV replication, confirming the previous observations with PALA.
Taken together, our dual screening approach uncovers the pyrimidine pathway and its associated and regulatory proteins as host factors for HDV infection and targets for antiviral therapy.
Chronic hepatitis D is the most severe form of viral hepatitis, and at present time, no treatment allows robust viral clearance. Using a dual screening approach, we identified ESR1 and CAD as host factors and antiviral targets for HDV infection. The functional impact of the pyrimidine biosynthesis for HDV replication is corroborated by: (1) a marked decrease in HDV infection after CAD and ESR1 silencing; (2) a significant antiviral effect of CAD and ESR1 inhibitors PALA and fulvestrant; and (3) kinetic experiments mapping viral replication as the step of the viral life cycle mediated by these host factors and targeted by the antiviral (4) validation studies in primary human hepatocytes.
Whereas the molecular virology of HDV is well described, the molecular interactions between the virus and liver host factors are still largely unknown.5 In mammalian cells, the pyrimidine biosynthesis pathway leads to the production of de novo nucleotides and plays a key role in RNA and DNA production, as well as protein glycosylation or cell membrane assembly.25 Moreover, uridine nucleotides and derivatives regulate key physiological processes, such as lipid metabolism, regulation of normal central nervous system activity or modulation of reproduction,35 making this pathway a major actor of important metabolic processes. As a source of nucleotides for HDV RNA, this pathway is likely to be required for optimal virus replication. Moreover, as a key regulator of viral glycosylation,25 an alteration of this pathway may alter post-translational modification of host or viral proteins, disrupting viral infection.
CAD is a multifunctional enzyme exhibiting carbamoylphosphate synthetase, aspartate transcarbamoylase and dihydroorotase activities catalysing the three first steps of the pyrimidine biosynthesis pathway,36 playing a key role in HDV infection as such. The observed antiviral activity of the CAD-specific inhibitor PALA validates the importance of this factor and pathway in HDV infection. It is of interest to note that another enzyme of the pyrimidine biosynthesis pathway DHODH, which catalyses the production of orotate from DHO, has been described as an antiviral target by small molecule GSK983.37 Here, we confirmed that the CAD-mediated DHO and uridine starvation is responsible for the observed antiviral effect (figures 4 and 5). Interestingly, HSPG synthesis has been shown to be dependent on the pyrimidine synthesis pathway in a CAD-defective animal model.38 However, we did not observe any effect of CAD inhibition on either HBV infection or HDV entry (figure 5E–H). While recent studies have suggested that the inhibition of pyrimidine biosynthesis can stimulate innate antiviral responses,29 no induction of IFN expression was observed in our model (figure 4E). Thus, it is likely that the modulation of CAD activity or expression affects HDV infection through its classical enzymatic activity linked to pyrimidine metabolism, mainly affecting viral replication through uridine starvation, affecting both genomic and antigenomic HDV RNAs. In this context, our study suggests that the first steps of replication are particularly susceptible to PALA. These results are consistent with the timing of HDV RNA amplification, much more pronounced during the early phase of replication, before L-HDAg-mediated slowdown of replication.5
Among the genes regulating the pyrimidine pathway, we identified ESR1 as a HDV host-dependency factor and antiviral target. ESR1 is a nuclear hormone receptor expressed in the mammary gland and female reproductive track and also in lung and liver.39 In our mechanistic analyses, we show that ESR1 inhibition by fulvestrant led to a decrease in CAD protein expression, which most likely explains the antiviral effect of the molecule.
Our screening strategy also identified small molecules exhibiting significant antiviral activity against HDV infection. Among them was found ribavirin, a nucleoside analogue previously used for the treatment of chronic HCV infection.40 Given its concentration in the primary screen (10 µM), HDV inhibition is most likely due to the ability of ribavirin to inhibit de novo synthesis of GTP as recently suggested as a possible mechanism for the inhibition of hepatitis E virus (HEV) replication in Huh7 cells (IC50 of 18.9 µM for GTP depletion; EC50 of 3 µM for HEV replication41). However, clinical attempts to treat hepatitis D using ribavirin were largely unsuccessful.4
Collectively, we identified previously undiscovered pathways and host factors for HDV infection and antiviral targets. Host-targeting agents are a promising approach for the development of new antiviral treatments, notably because they limit the emergence of resistant variants.8–10 42 In particular for RNA viruses, which do not integrate into the genome, host-targeting agents hold promise for viral cure.43 Indeed, in chronic HCV infection antibodies targeting a viral host entry factor claudin-1 cure viral infection in a state-of-the-art mouse model,12 and a miRNA-122 antagonist has been shown to cure chronic HCV infection in monotherapy in a subset of patients.44 Two host compounds targeting HDV factors have been developed up to clinical proof of concept: these include Myrcludex B, a small peptide-targeting HBV/HDV entry factor NTCP and the prenylation inhibitor lonafranib.4 13 14 In randomised clinical trials, both compounds demonstrated a significant and robust antiviral effect in chronically infected patients,4 13 14 supporting the validity of the concept of host-targeting antivirals for HDV infection. However, long-term safety, potential resistance in subsets of patients and data on sustained virological response remain to be determined. The discovery of novel host factors described in this study may overcome these limitations by complementary, safer and more efficient approaches. Compounds targeting essential host factors of the viral replication step may be conceptually superior to entry or prenylation inhibitors by targeting the most vulnerable step of the viral life cycle. Indeed, viral replication is the target of many effective clinically licenced antiviral therapies such as nucleoside analogues for HBV infection or polymerase/protease inhibitors for HIV and HCV infection.
A theoretical disadvantage of HTA is their putative adverse effects on physiological processes mediated by the host factors. In this context, given that an HDV treatment will occur in a context of diseased liver, assessment of safety will be a major parameter in development. In this regard, it is of interest to note that pyrimidine synthesis inhibitors, such as leflunomide or teriflunomide, are currently used for the treatment of rheumatoid arthritis and multiple sclerosis.45 46 The safety profile of these compounds suggests that pyrimidine biosynthesis is a targetable pathway for antiviral strategies. Indeed, the FDA-approved leflunomide, targeting DHODH, induces uridine starvation at concentrations similar to PALA concentrations we used in this study (0–100 µM).47 Although detailed toxicity analyses in animal model and human tissues will be required to assess the therapeutic window of PALA, the dose–response effects of leflunomide suggests that PALA doses required to inhibit HDV infection are most likely in a range that will have an acceptable clinical safety profile.
In conclusion, by uncovering key host factors for HDV infection our results significantly improve the understanding of the HDV life cycle and contribute to the development of novel antiviral strategies for HDV cure.
Material and methods
Human serum from patients with chronic HBV/HDV infection followed at the Strasbourg University Hospitals, Strasbourg, France, was obtained with informed consent. PHHs were obtained from liver tissue from patients undergoing liver resection for liver metastasis at the Strasbourg University Hospitals with informed consent.
Cell lines and human hepatocytes
Fulvestrant (I4409), DL-dihydroorotic acid (DHO, D7003), L-glutamine (59 202C), uridine (U3003) and TFV (1643601) were purchased from Sigma-Aldrich (Merck). Sparfocid acid (L-Aspartic acid, N-(phosphonoacetyl)-, disodium salt (9 CI) or PALA, NSC: 224131) was first obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA. For further analyses, PALA was synthetised at the Institute of Chemistry, University of Strasbourg, as described in online supplementary material and methods. PreS1 peptide was synthetised by Bachem.7
HDV and HBV production and infection
The production of recombinant HDV and HBV infectious virus as well as the protocol for HDV infection of Huh-106 cells and PHHs and for HBV infection of HepG2-NTCP cells have been described.7 49 50 A detailed protocol is presented in online supplementary material and methods.
RNAi loss-of-function and small molecule screens
Screening was performed at the High Throughput Screening platform of the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Illkirch, France. The Human ON-TARGETplus ‘Druggable Genome’ siRNA Library was used for gene expression silencing. For the small molecule screen, the Chemical Library (PCL) containing 1280 FDA-approved molecules was obtained from Prestwick. Detailed information about both screening strategies as well as the algorithm for selection of HDV-dependency candidates are presented in online supplementary material and methods.
Validation of CAD as a HDV host factor using individual siRNAs
Huh-106 cells were reverse-transfected with the four individual siRNAs from the siCAD pool, a pool of siRNA targeting SLC10A1 (siNTCP) or a non-targeting siRNA control (siCtrl) using lipofectamin RNAi max as described.7 50 Gene expression was assessed, 2 days after transfection, by western blot detection of CAD protein using a rabbit monoclonal anti-CAD antibody (Abcam ab40800) as previously described.7 50 β-actin expression was assessed as a loading control using a mouse monoclonal anti-β-actin antibody (Sigma, A5441). Two days after transfection, cells were infected by HDV, and infection was assessed after 7 days as described in online supplementary material and methods.
All experiments were performed at least twice in an independent manner. Statistical analyses were performed using a two-tailed Mann-Whitney U test unless otherwise stated; p<0.05 (*), p<0.01 (**) and p<0.001 (***) were considered statistically significant. Significant p values are indicated by asterisks in the individual figures and figure legends. The number of biological replicates is indicated in the figure legends (n).
Additional methodological information are available in online supplementary material.
We would like to thank J Taylor (Fox Chase Cancer Center) for the gift of the HDV expression plasmid (pSVL(D3)) and our colleagues S Durand and M Renaud for excellent technical support. We thank the INGESTEM infrastructure for access to the IGBMC high-throughput high-content screening workstation.
Contributors TB initiated the study. TB and ERV designed and supervised research. ERV, AW, LB and TB set up, designed and performed the siRNA and small molecule screens. TG and PPa produced the sparfosic acid. ERV, CB, LH, VT-L and EC performed the validation experiments. CSu performed the HDV northern blots. PPe provided human hepatocytes. ERV, AW, CB, LH, EC, MBZ, CSu, CSc, LB and TB analysed the data. ERV, HES and AK performed the bioinformatical analyses of the screens. EV and TB wrote the manuscript. All the authors approved the study.
Funding This work was supported by Inserm, the University of Strasbourg, the European Union (Infect-ERA hepBccc, ERC-2014-AdG-671231-HEPCIR and Horizon 2020 research and innovation programme under grant agreement 667273 - HEPCAR), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS 15/1099) and the French Cancer Agency (ARC IHU201301187). This work has been published under the framework of the LabEx ANR-10-LAB-28 and benefits from a funding from the state managed by the French National Research Agency as part of the Investments for the Future (Investissements d’Avenir) programme. ERV is the recipient of an ANRS fellowship (ECTZ50121).
Competing interests None declared.
Ethics approval Protocols were approved by the local Ethics Committee of the Strasbourg University Hospitals (CPP) and the Ministry of Higher Education and Research of France (DC 2016 2616).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The datasets generated in this study, including the results from both RNAi and small molecule primary screens, are available within online supplementary material files. The rest of the data are available from the corresponding authors on reasonable request.